Loading
FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.79, animal model 0.49, genetic association 0.00, clinical 0.96).
In plain words · FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration.
No product in this corpus aims at FGR yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FGR: RNA group enriched (bone marrow 197 nTPM, lung 83 nTPM, lymphoid tissue 136 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas FGR tissue; Open Targets ENSG00000000938 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Nishizawa et al, Mol. Cell. Biol, 1986, "Structure, expression, and chromosomal location of the human c-fgr gene". Source.
Sources: HGNC HGNC:3697 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09769 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000000938 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.55, non-Hodgkin lymphoma 0.55, chronic myelogenous leukaemia, BCR-ABL1 positive 0.58, myeloproliferative neoplasm 0.60, leukaemia 0.61 (GraphQL API, CC0))
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B. Acts downstream of ITGB1 and ITGB2, and regulates actin cytoskeleton reorganisation, cell spreading and adhesion. Depending on the context, activates or inhibits cellular responses. Functions as a negative regulator of ITGB2 signalling, phagocytosis and SYK activity in monocytes. Location: Cell membrane; Cell projection, ruffle membrane; Cytoplasm, cytosol; Cytoplasm, cytoskeleton (UniProt). Locus 1p35.3 (HGNC).
RNA: group enriched (bone marrow 197 nTPM, lung 83 nTPM, lymphoid tissue 136 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Bone marrow, Lung, Lymph node, Spleen, Tonsil.
No cancer stained high; medium in breast cancer, carcinoid, colorectal cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FGR" OR ABSTRACT:"FGR" OR TITLE:"FGR proto-oncogene, Src family tyrosine kinase" OR ABSTRACT:"FGR proto-oncogene, Src family tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Fgr" OR ABSTRACT:"Tyrosine-protein kinase Fgr" OR TITLE:"c-fgr" OR ABSTRACT:"c-fgr" OR TITLE:"p55c-fgr" OR ABSTRACT:"p55c-fgr" OR TITLE:"SRC2" OR ABSTRACT:"SRC2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGR, not a curated reading list.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.